vs
ANI PHARMACEUTICALS INC（ANIP）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是ANI PHARMACEUTICALS INC的1.9倍（$461.6M vs $247.1M），RBC Bearings INC净利率更高（14.6% vs 11.1%，领先3.5%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 17.0%），RBC Bearings INC自由现金流更多（$99.1M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 5.6%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
ANIP vs RBC — 直观对比
营收规模更大
RBC
是对方的1.9倍
$247.1M
营收增速更快
ANIP
高出12.6%
17.0%
净利率更高
RBC
高出3.5%
11.1%
自由现金流更多
RBC
多$70.0M
$29.1M
两年增速更快
ANIP
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $461.6M |
| 净利润 | $27.5M | $67.4M |
| 毛利率 | — | 44.3% |
| 营业利润率 | 14.1% | 22.3% |
| 净利率 | 11.1% | 14.6% |
| 营收同比 | 29.6% | 17.0% |
| 净利润同比 | 367.5% | 16.4% |
| 每股收益（稀释后） | $1.14 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRBC
| Q4 25 | $247.1M | $461.6M | ||
| Q3 25 | $227.8M | $455.3M | ||
| Q2 25 | $211.4M | $436.0M | ||
| Q1 25 | $197.1M | $437.7M | ||
| Q4 24 | $190.6M | $394.4M | ||
| Q3 24 | $148.3M | $397.9M | ||
| Q2 24 | $138.0M | $406.3M | ||
| Q1 24 | $137.4M | $413.7M |
净利润ANIPRBC
| Q4 25 | $27.5M | $67.4M | ||
| Q3 25 | $26.6M | $60.0M | ||
| Q2 25 | $8.5M | $68.5M | ||
| Q1 25 | $15.7M | $72.7M | ||
| Q4 24 | $-10.3M | $57.9M | ||
| Q3 24 | $-24.2M | $54.2M | ||
| Q2 24 | $-2.3M | $61.4M | ||
| Q1 24 | $18.2M | — |
毛利率ANIPRBC
| Q4 25 | — | 44.3% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | — | 44.8% | ||
| Q1 25 | — | 44.2% | ||
| Q4 24 | — | 44.3% | ||
| Q3 24 | — | 43.7% | ||
| Q2 24 | — | 45.3% | ||
| Q1 24 | — | 43.1% |
营业利润率ANIPRBC
| Q4 25 | 14.1% | 22.3% | ||
| Q3 25 | 15.9% | 21.5% | ||
| Q2 25 | 6.6% | 23.2% | ||
| Q1 25 | 13.3% | 23.0% | ||
| Q4 24 | -2.3% | 21.7% | ||
| Q3 24 | -13.8% | 21.6% | ||
| Q2 24 | 3.7% | 24.0% | ||
| Q1 24 | 14.8% | 22.8% |
净利率ANIPRBC
| Q4 25 | 11.1% | 14.6% | ||
| Q3 25 | 11.7% | 13.2% | ||
| Q2 25 | 4.0% | 15.7% | ||
| Q1 25 | 8.0% | 16.6% | ||
| Q4 24 | -5.4% | 14.7% | ||
| Q3 24 | -16.3% | 13.6% | ||
| Q2 24 | -1.7% | 15.1% | ||
| Q1 24 | 13.2% | — |
每股收益（稀释后）ANIPRBC
| Q4 25 | $1.14 | $2.13 | ||
| Q3 25 | $1.13 | $1.90 | ||
| Q2 25 | $0.36 | $2.17 | ||
| Q1 25 | $0.69 | $2.33 | ||
| Q4 24 | $-0.45 | $1.82 | ||
| Q3 24 | $-1.27 | $1.65 | ||
| Q2 24 | $-0.14 | $1.90 | ||
| Q1 24 | $0.82 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $540.7M | $3.3B |
| 总资产 | $1.4B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ANIPRBC
| Q4 25 | $285.6M | $107.6M | ||
| Q3 25 | $262.6M | $91.2M | ||
| Q2 25 | $217.8M | $132.9M | ||
| Q1 25 | $149.8M | $36.8M | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | $76.8M | ||
| Q1 24 | $228.6M | $63.5M |
总债务ANIPRBC
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
股东权益ANIPRBC
| Q4 25 | $540.7M | $3.3B | ||
| Q3 25 | $505.8M | $3.2B | ||
| Q2 25 | $436.8M | $3.1B | ||
| Q1 25 | $418.6M | $3.0B | ||
| Q4 24 | $403.7M | $2.9B | ||
| Q3 24 | $405.9M | $2.9B | ||
| Q2 24 | $455.8M | $2.8B | ||
| Q1 24 | $452.0M | $2.8B |
总资产ANIPRBC
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.3B | $4.8B | ||
| Q1 25 | $1.3B | $4.7B | ||
| Q4 24 | $1.3B | $4.7B | ||
| Q3 24 | $1.3B | $4.7B | ||
| Q2 24 | $920.8M | $4.7B | ||
| Q1 24 | $914.5M | $4.7B |
负债/权益比ANIPRBC
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $99.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 21.5% |
| 资本支出强度资本支出/营收 | 0.5% | 5.0% |
| 现金转化率经营现金流/净利润 | 1.10× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPRBC
| Q4 25 | $30.4M | $122.1M | ||
| Q3 25 | $44.1M | $88.4M | ||
| Q2 25 | $75.8M | $120.0M | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $15.9M | $84.0M | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $17.4M | $97.4M | ||
| Q1 24 | $18.3M | — |
自由现金流ANIPRBC
| Q4 25 | $29.1M | $99.1M | ||
| Q3 25 | $38.0M | $71.7M | ||
| Q2 25 | $71.8M | $104.3M | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | $73.6M | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | $88.4M | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPRBC
| Q4 25 | 11.8% | 21.5% | ||
| Q3 25 | 16.7% | 15.7% | ||
| Q2 25 | 34.0% | 23.9% | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | 18.7% | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | 21.8% | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPRBC
| Q4 25 | 0.5% | 5.0% | ||
| Q3 25 | 2.7% | 3.7% | ||
| Q2 25 | 1.9% | 3.6% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 1.3% | 2.6% | ||
| Q3 24 | 3.2% | 4.1% | ||
| Q2 24 | 3.2% | 2.2% | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPRBC
| Q4 25 | 1.10× | 1.81× | ||
| Q3 25 | 1.66× | 1.47× | ||
| Q2 25 | 8.87× | 1.75× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.59× | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
